From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation
Jump to search
|
|
Line 17: |
Line 17: |
| ==Antiestrogen therapy== | | ==Antiestrogen therapy== |
| | | |
− | =Docetaxel-containing regimen=
| |
| =Fludarabine-based regimen= | | =Fludarabine-based regimen= |
| | | |
Revision as of 01:24, 25 May 2021
The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.
Alkylator-based regimen
Anthracycline-based regimen
Anti-CD20-based regimen
Rituximab-containing regimen
Anti-HER2-based regimen
Trastuzumab-based regimen
Anti-VEGF biologic therapy
Bevacizumab-containing regimen
Endocrine-based regimen
Androgen receptor-directed therapy
Antiestrogen therapy
Fludarabine-based regimen
Fluoropyrimidine-based regimen
5-FU-based regimen
Irinotecan-based regimen
Pemetrexed-containing regimen
Platinum-based regimen
Cisplatin-based regimen
Oxaliplatin-based regimen
Platinum-based chemoradiation
Platinum doublet
Single-agent regimen
Single-agent cytotoxic chemotherapy
Single-agent hormonotherapy
Single-agent immunotherapy
Single-agent targeted therapy
Taxane-based regimen
Tyrosine kinase inhibitor therapy
BRAF TKI therapy
EGFR TKI therapy
VEGFR inhibitor therapy